Hepatocyte growth factor profile with breast cancer

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 3, 2011, Pages 509-513

  El Attar, Hoda A ^a   Sheta, Manal I ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Breast lumps; hepatocyte growth factor; immunohistochemistry; prognostic parameters

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; GLUCOSE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TUMOR MARKER; UREA; URIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPIRATION BIOPSY; BREAST CARCINOMA; BREAST FIBROADENOMA; BREAST TUMOR; CLINICAL EXAMINATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOLOGY; DISEASE MARKER; FEMALE; FIBROCYSTIC BREAST DISEASE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PROGNOSIS; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053901842     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.85083     Document Type: Article

References (29)

1. Ma J, DeFrances MC, Zou C, Johnson C, Ferrell R, Zarnegar R. Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest 2009;119:478-91.
2. Favoni RE, De Cupis A. The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach. Pharmacol Rev 2000;52:179-206.
3. Liu Y. Hepatocyte growth factor in kidney fibrosis: Therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004;287:7-16.
4. Parr C, Watkins G, Mansel RE, Jiang WG. The Hepatocyte growth factor regulatory factor, in human breast cancer. Clin Cancer Res 2004;10:202-11.
5. Ohnishi T, Kakimoto K, Bandow K, Lowenstein CJ, Daikuhara Y, Matsuguchi T. Mature Hepatocyte growth factor/Scatter factor on the surface of human granulocytes is released by a mechanism involving activated Factor Xa. J Immunol 2006;176:6945-53.
6. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12:3657-60.
7. Pollard JW. Tumor-stromal interactions: Transforming growth factorbeta isoforms and hepatocyte growth factor/scatter factor in mammary gland ductal morphogenesis. Breast Cancer Res 2001;3:230-7.
8. Matteucci E, Ridolfi E, Maroni P, Bendinelli P, Desiderio MA. c- Src/ Histone Deacetylase 3 interaction is crucial for Hepatocyte Growth Factor-Dependent decrease of CXCR4 expression in highly invasive breast tumor cells. Mol Cancer Res 2007;5:833-45.
9. Guray M, Sahin AA. Benign Breast Diseases: Classification, Diagnosis and Management. Oncologist 2006;11:435-49.
10. Celis JE, Gromov P, Moreira JM, Cabe'zon T, Friis E, Vejborg JM, et al. Apocrine cysts of the breast. Biomarkers, origin, enlargement and relation with cancer phenotype. Mol Cell Proteomics 2006;5:462-83.
11. Ridolfi E, Matteucci E, Maroni P, Desiderio MA. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and the role of HDACs. Br J Cancer 2008;99:1623-34.
12. Sheen-Chen SM, Liu YW, Eng HL, Chou FF. Serum levels of Hepatocyte Growth Factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:715-7.
13. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. St Louis: Elsevier Saunders Company; 2006. p. 870-1, 802,798,807-8,604-7 609-10.
14. Hondermarckh. Breast cancer when proteomics challenge biological complexity. Mol Cell Proteomics 2003;2:281-91.
15. Sattler M, Salgia R. The MET axis as a therapeutic target. Update Cancer Ther 2009;1:109-18.
16. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995;1:1031-4.
17. Jin L, Fuchs A, Schnett SJ, Yao Y, Joseph A, Lamszus K, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997;79:749-60.
18. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in earlystage breast cancer. Oncologist 2004;9:606-16.
19. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met)in human breast carcinoma. Am J Pathol 1996;148:225-32.
20. Matteucci E, Bendinelli P, Desiderio MA. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 2009;30:937-45.
21. Rahimi-Hung W, Tremblay E, Saulnier R, Elliott B. C-Src Kinase activity is required for Hepatocyte Growth Factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem 1998;273:33714-21.
22. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor on human breast carcinoma: Correlation with tumor progression. Int J Cancer 1997;74:301-9.
23. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001;411:375-9.
24. Wang X, Li K, Chen H, Wang D, Zhang Y, Bai C. Does hepatocyte growth factor/c-Met signal play synergistic role in lung cancer? J Cell Mol Med 2010;4:833-9.
25. Sung HJ, Kim SY, Kim CK, Choi JR, Song KS. Clinical usefulness of circulating Hepatocyte Growth Factor in breast cancer. Korean J Lab Med 2003;23:309-14.
26. Yamashita JI, Ogawa M, Yamashita SI, Nomura K, Kuramoto M, Saishoji T, et al. Immunoreactive Hepatocyte Growth Factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-3.
27. Wei-Kai H, Yu-xiu, Ting Y, Li Z, Wen-wen Z, Chun-Li F, et al. Adipocytokines and breast cancer risk. Chin Med J 2007;120:1592-5.
28. Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastasis from breast cancer. Tumour Biol 2007;28:36-44.
29. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005;53:35-69.